{
    "data": [
        {
            "title": "Berkshire Hathaway (BRK.A) Valuation Check After Recent Short Term Share Price Moves",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Short term moves and recent performance context</h2> <p>Berkshire Hathaway (BRK.A) recently closed at US$757,000, with the stock showing a 0.5% move over the past day and a 1.4% gain across the past week, keeping short term performance in focus for investors.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-brk.a/berkshire-hathaway\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Berkshire Hathaway.</a></p> <p>That recent 6% 1 month share price return comes after a softer 90 day share price return of a 1.7% decline and sits alongside a 3 year total shareholder return of about 60%. This suggests longer term holders have still seen solid compounding despite recent hesitation.</p> <p>If Berkshire‚Äôs moves have you thinking about where else long term wealth might be built, now could be a good time to broaden your search with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With Berkshire trading close to analyst targets yet sitting on an estimated 40% intrinsic discount, the real question for you is whether there is still a long term entry point here or if the market is already pricing in future growth.</p> <h2>Most Popular Narrative: 19.8% Undervalued</h2> <p>At $757,000 per share, Berkshire Hathaway sits below the narrative fair value of about $943,786, which frames the company as materially undervalued according to davidlsander.</p> <blockquote> <p><em>Berkshire Hathaway's combination of financial strength, disciplined investment approach, and strong leadership is described as making it a compelling investment option. The narrative links this view to the company's historical performance and a positive outlook for its future, and suggests that a net inflation growth of 12-15% in the share price is considered achievable. It also notes that investors who are willing to adopt a long-term perspective and who appreciate the value of quality companies may view Berkshire Hathaway as a potentially rewarding investment.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/wfyk21cn-berkshire-hathaway-a-fortress-of-financial-strength\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>The narrative highlights a valuation gap and discusses the confidence in potential long-term returns. It leans heavily on revenue growth assumptions, firm margins, and a future earnings multiple that together imply ongoing compounding at scale for Berkshire. For readers who want to see which specific assumptions and figures drive that fair value, the full story lays out the numbers in detail.</p> <p><strong>Result: Fair Value of $943,786 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_user_generated_narrative\" href=\"https://www.simplywall.st/narratives/wfyk21cn-berkshire-hathaway-a-fortress-of-financial-strength\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this view could be challenged if revenue growth of 13.0% or the assumed 18.3344% profit margin prove optimistic, or if leadership transition expectations shift materially.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-brk.a/berkshire-hathaway\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Berkshire Hathaway narrative.</a></p> <h2>Next Steps</h2> <p>Given the mix of optimism and caution in this narrative, it makes sense to look at the data yourself rather than wait for market consensus. To assess both the key concerns and the potential upsides in one place, take a look at the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-brk.a/berkshire-hathaway\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Berkshire has you thinking more seriously about your portfolio, now is the moment to line up a few high quality alternatives before the next big move.</p> <ul> <li>Start by tightening your risk profile and focus on stability with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">76 resilient stocks with low risk scores</a>, so you are not caught off guard by the next rough patch.</li> <li>Hunt for quality at a sensible price using the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> to see which companies currently line up with your return expectations and comfort level.</li> <li>Build a watchlist of future contenders that the market might be overlooking by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> before everyone else catches on.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Berkshire Hathaway might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/diversified-financials/nyse-brk.a/berkshire-hathaway/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 08:35:59",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nyse-brk.a/berkshire-hathaway/news/berkshire-hathaway-brka-valuation-check-after-recent-short-t",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Perella Weinberg (PWP) Quietly Redefining Earnings Resilience Despite a Modest Revenue Decline?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Perella Weinberg Partners recently reported quarterly revenues of US$219.2 million, a 2.9% year-on-year decline that still exceeded analyst estimates by a very large margin, alongside an earnings beat.</li> <li>The results highlight how the firm‚Äôs operational execution outpaced expectations even as headline revenue slipped, offering a more nuanced picture of performance for investors.</li> <li>Next, we‚Äôll examine how this better-than-expected revenue performance shapes Perella Weinberg Partners‚Äô investment narrative and its perceived earnings resilience.</li> </ul><p>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>What Is Perella Weinberg Partners' Investment Narrative?</h2><p>To own Perella Weinberg Partners, you have to believe in the durability of its advisory franchise, its ability to turn fee volatility into consistent profitability, and the discipline behind its capital returns. The latest quarter, with US$219.2 million in revenue modestly lower year on year but far ahead of expectations, reinforces the near term catalyst that matters most: evidence that the firm can beat a conservative profit bar even when activity is mixed. That sits alongside a still-young management team, a relatively high earnings multiple, and recent share price weakness despite an earnings beat, which together sharpen the risk that sentiment can swing quickly if deal flow or margins soften. For now, the new results look more sentiment reset than thesis changer.</p> However, one key risk around valuation and execution is easy to miss at first glance.\n\nPerella Weinberg Partners' share price has been on the slide but might be dropping deeper into value territory. <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-pwp/perella-weinberg-partners/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Find out whether it's a bargain at this price</a>.<h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-pwp/perella-weinberg-partners\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PWP 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/a24e2b09-9cf0-4c00-b003-7179c869df72/chart/quote-price\" width=\"746\"/></a><figcaption>PWP 1-Year Stock Price Chart</figcaption></figure> The single fair value from the Simply Wall St Community clusters at US$25.63, suggesting a tight, optimistic view. Set against PWP‚Äôs recent earnings beat and share price pullback, it underlines how differently investors can frame both risk and resilience.<p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nasdaq-pwp/perella-weinberg-partners\" rel=\"noopener noreferrer\" target=\"_blank\">Explore another fair value estimate on Perella Weinberg Partners</a> - why the stock might be worth just $25.62!</p><h2>Form Your Own Verdict</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Perella Weinberg Partners research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-pwp/perella-weinberg-partners\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-pwp/perella-weinberg-partners\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Perella Weinberg Partners research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Perella Weinberg Partners' overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">31 elite penny stocks</a> that balance risk and reward.</li><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 08:35:59",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nasdaq-pwp/perella-weinberg-partners/news/is-perella-weinberg-pwp-quietly-redefining-earnings-resilien",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Aichi Steel (TSE:5482) Valuation After Governance Overhaul To Strengthen Board Oversight",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Aichi Steel (TSE:5482) has put corporate governance in focus after its February 27 board meeting, where directors backed a shift to a company with an Audit and Supervisory Committee, pending shareholder approval in June.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-5482/aichi-steel-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Aichi Steel.</a></p> <p>The governance shift comes as the stock has been on a strong run, with a 1 day share price return of 4.32% and a 30 day share price return of 11.62%. The 1 year total shareholder return is about double and the 3 year total shareholder return is a little over 5x, pointing to momentum that has already reshaped how the market is pricing Aichi Steel‚Äôs progress.</p> <p>If these moves have you thinking about where else strong governance and execution could show up next, it might be worth scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/jp\" rel=\"noopener noreferrer\" target=\"_blank\">12 top founder-led companies</a> as a way to surface fresh ideas beyond Aichi Steel.</p> <p>With the shares already delivering very large multi year returns and trading at about a 6% intrinsic discount, the key question now is whether Aichi Steel is still cheap or if the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Preferred P/E of 19.1x: Is It Justified?</h2> <p>On the numbers, Aichi Steel is trading on a P/E of 19.1x, while our DCF work suggests the shares are at about a 94.5% discount to an estimated future cash flow value of ¬•63,651.95 per share versus a last close of ¬•3,505. That mix of a relatively high earnings multiple and a very large modelled discount is what many investors will want to unpack.</p> <p>The P/E ratio compares the current share price with earnings per share. A 19.1x multiple effectively indicates how much the market is paying for each unit of current earnings. For a metals and mining name that is not a bank, this is a common way to benchmark sentiment around the earnings stream.</p> <p>However, Aichi Steel‚Äôs P/E of 19.1x is described as expensive relative to both the JP Metals and Mining industry average of 14.5x and a peer average of 11.8x. That suggests the market is attaching a richer price tag to its earnings than many peers. At the same time, our DCF model, which projects future cash flows and discounts them back to today, points to a very large gap between the current ¬•3,505 price and a theoretical ¬•63,651.95 value.</p> <p>Compared with industry and peer P/E levels, the premium is clear and sizeable. Any investor leaning on this multiple has to judge whether the earnings profile and recent profit growth justify paying more than the sector and peer norms.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-5482/aichi-steel-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p><strong>Result: Price-to-Earnings of 19.1x (OVERVALUED)</strong></p> <p>However, you also have to weigh risks such as earnings not supporting a 19.1x P/E and any governance changes failing to translate into consistent operational discipline.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-5482/aichi-steel-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Aichi Steel narrative.</a></p> <h2>Another View: DCF Suggests A Very Different Price</h2> <p>While the 19.1x P/E points to an expensive share price relative to industry and peers, our DCF model paints the opposite picture, with Aichi Steel at ¬•3,505 compared with an estimated future cash flow value of ¬•63,651.95. That gap raises a simple question: which signal do you trust more, the earnings multiple or the cash flow model?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-5482/aichi-steel-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/materials/tse-5482/aichi-steel-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"5482 Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/95517a98-2859-4939-b161-4c983a62acd9/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>5482 Discounted Cash Flow as at Feb 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-5482/aichi-steel-shares\" rel=\"noopener noreferrer\" target=\"_blank\">check out Aichi Steel for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>If this mix of signals feels mixed to you, that is the point. The best next step is to look at the full picture for yourself, starting with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-5482/aichi-steel-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 1 important warning sign</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Aichi Steel has sharpened your thinking, do not stop here. Use the screener to line up your next watchlist candidates while the market is still moving.</p> <ul> <li>Spot potential bargains early by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a>, which combine quality fundamentals with prices that may not fully reflect them.</li> <li>Prioritise resilience with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/jp\" rel=\"noopener noreferrer\" target=\"_blank\">57 resilient stocks with low risk scores</a>, focusing on companies that score well on risk factors so sudden shocks are less likely to catch you off guard.</li> <li>Hunt for fresh names beyond the usual benchmarks using our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/jp\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 58 high quality undiscovered gems</a>, where underfollowed companies with solid fundamentals are easier to find.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 08:35:59",
            "link": "https://simplywall.st/stocks/jp/materials/tse-5482/aichi-steel-shares/news/assessing-aichi-steel-tse5482-valuation-after-governance-ove",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Applied Optoelectronics (AAOI) Narrower Q4 Loss Tests Bullish Earnings Ramp Narrative",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Applied Optoelectronics (AAOI) closed out FY 2025 with fourth quarter revenue of US$134.3 million and a basic EPS loss of US$0.03, alongside net income excluding extra items of a US$2.0 million loss. This puts the focus squarely on how efficiently that top line is being converted into earnings. The company has seen quarterly revenue move from US$65.2 million in Q3 2024 to US$100.3 million in Q4 2024, then to US$99.9 million in Q1 2025, US$103.0 million in Q2 2025, US$118.6 million in Q3 2025 and US$134.3 million in Q4 2025. Over those same periods, basic EPS ranged from a loss of US$2.60 to a loss of US$0.03, setting up a story where revenue momentum is bumping up against still pressured margins.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-aaoi/applied-optoelectronics\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Applied Optoelectronics.</a> <p>With the headline numbers on the table, the next step is to see how this mix of growing revenue and ongoing losses lines up with the widely followed growth and risk narratives around AAOI, and where those stories might need updating.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/2saym4qr-ai-expansion-and-wireless-rollouts-will-reshape-optical-communications\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about Applied Optoelectronics</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-aaoi/applied-optoelectronics/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:AAOI Revenue &amp; Expenses Breakdown as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/c766e9d2-2b53-4136-b901-5a850ef40d01/chart/revenue-and-expenses-breakdown?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGM:AAOI Revenue &amp; Expenses Breakdown as at Feb 2026</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>US$455.7m in sales still paired with TTM loss</h2> <ul> <li>On a trailing twelve month basis, AAOI generated US$455.7 million in revenue and reported a net loss excluding extra items of US$38.2 million, with TTM basic EPS at a loss of US$0.64.</li> <li>Consensus narrative expects revenue to grow 51.5% per year with margins moving from a loss of 42.3% to an 8.7% profit margin over three years, yet the latest TTM loss and negative EPS show that the company is still in the loss making phase today.\n    <ul> <li>Analysts see earnings shifting from a loss of US$155.7 million to a profit of US$111.0 million by around 2028, while the most recent TTM net loss of US$38.2 million indicates a smaller loss than that reference point but still not a profit.</li> <li>This gap between current losses and future profit expectations is a key part of the consensus view, which links the current revenue base of US$455.7 million to much higher forecast revenue of US$1.3b.</li> </ul> </li> </ul> <h2>Loss trend vs high growth forecasts</h2> <ul> <li>Over the last twelve months AAOI remained unprofitable and its losses have grown at about 21.6% per year over the past five years, even as revenue is forecast to grow 57% per year and earnings are forecast to rise at 140.91% per year with profitability expected within three years.</li> <li>Bulls argue that rapid adoption of 400G and 800G products, plus margin expansion from vertical integration, can support this strong earnings ramp, but the history of growing losses gives a very different reference point.\n    <ul> <li>The bullish narrative points to margins moving from a 42.3% loss to an 18.6% profit margin and earnings reaching US$318.0 million, which sits in sharp contrast to the recent TTM net loss of US$38.2 million and five year loss growth rate of 21.6% a year.</li> <li>Supporters also assume revenue rising to about US$1.7b, a multiple of the current US$455.7 million TTM level, so the thesis relies on the business scaling several times larger while reversing a multiyear loss pattern.</li> </ul> </li> </ul> Have bulls already priced in a best case ramp for AAOI, or is the current loss history masking future earnings power in plain sight? <a class=\"company-report-links\" data-vars-link-type=\"cta_bull_narrative_link\" href=\"https://simplywall.st/narratives/2saym4qr-ai-expansion-and-wireless-rollouts-will-reshape-optical-communications\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêÇ Applied Optoelectronics Bull Case</strong></a> <h2>Rich P/S multiple and dilution risks</h2> <ul> <li>The shares trade on a P/S of 13.9x compared with 1.9x for the broader US Communications industry and 2.8x for peers, while shareholders have also faced substantial dilution over the past year alongside a DCF fair value estimate of US$109.22 that sits well above the current share price of US$84.23.</li> <li>Bears focus on that high multiple and dilution, arguing that dependence on a small number of large customers and heavy capital needs leave limited room for error even if revenue continues to grow.\n    <ul> <li>With the top 10 customers accounting for 98% of revenue and two customers making up 88%, the high P/S of 13.9x is being supported by a concentrated revenue base rather than a broad mix of customers.</li> <li>Ongoing expectations for share count to grow 7% per year over the next three years also line up with the recent dilution, which can spread any future earnings recovery over a larger number of shares.</li> </ul> </li> </ul> If AAOI needs years of high spending and faces concentrated customers, some investors may question whether this valuation and dilution mix leaves enough margin for safety. <a class=\"company-report-links\" data-vars-link-type=\"cta_bear_narrative_link\" href=\"https://simplywall.st/narratives/o0f8krux-customer-dependence-and-price-pressure-will-curtail-margins\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêª Applied Optoelectronics Bear Case</strong></a> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/2saym4qr-ai-expansion-and-wireless-rollouts-will-reshape-optical-communications\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for Applied Optoelectronics on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>After reading both the bullish and bearish angles, your own judgment matters most. Use the full data set to test your view and weigh up the company‚Äôs balance of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-aaoi/applied-optoelectronics\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a>.</p> <h2>See What Else Is Out There</h2> <p>AAOI pairs a rich 13.9x P/S multiple and ongoing losses with concentrated customers and dilution expectations, which may leave some investors uneasy about risk.</p> <p>If that mix of losses, customer concentration and dilution feels too intense, you may prefer companies in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">76 resilient stocks with low risk scores</a> that focus on more resilient fundamentals right now.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 08:35:59",
            "link": "https://simplywall.st/stocks/us/tech/nasdaq-aaoi/applied-optoelectronics/news/applied-optoelectronics-aaoi-narrower-q4-loss-tests-bullish",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "How Investors Are Reacting To Ecolab (ECL) Co-COO Reshuffle And New Debt Shelf Registration",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Earlier this month, Ecolab‚Äôs board reshaped its senior team by adding the President title to Chairman and CEO Christophe Beck and splitting the chief operating officer role between Darrell R. Brown as Co-COO ‚Äì Global Markets and Gregory B. Cook as Co-COO ‚Äì Global Businesses, while director Victoria J. Reich decided not to stand for re-election and the company affirmed its US$0.73 quarterly dividend.</li> <li>These leadership changes, alongside a new shelf registration for debt securities, suggest Ecolab is refining its global operating model and financial flexibility to support its One Ecolab priorities.</li> <li>Now we‚Äôll explore how appointing two Co-COOs with distinct global mandates could influence Ecolab‚Äôs existing investment narrative and execution focus.</li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">31 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Ecolab Investment Narrative Recap</h2><p>Ecolab‚Äôs story today is about disciplined execution on its One Ecolab initiative, pricing power and margin resilience in the face of cost and demand headwinds. The latest leadership reshuffle, including two Co-COOs with global remits, does not materially alter the near term catalyst around value pricing and digital-driven margin gains, nor the key risk that softer heavy industrial demand and cost inflation could pressure revenue and profits if pricing and efficiency actions fall short.</p> <p>Among the recent announcements, the new shelf registration for debt securities stands out as the most relevant alongside these leadership changes, as it adds financial flexibility while Ecolab invests in growth engines like Life Sciences and Ecolab digital. For investors focused on catalysts such as pricing initiatives and digital productivity, this additional funding option sits in the background, while execution on One Ecolab and customer acceptance of surcharges remain central to the story.</p> <p>Yet investors should be aware that if customer resistance to price surcharges intensifies and coincides with...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/materials/nyse-ecl/ecolab/yfhdr21m-margin-expansion-and-digital-solutions-will-drive-outperformance-over-the-next-few-years\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Ecolab (it's free!)</a></p><p>Ecolab's narrative projects $18.4 billion revenue and $2.8 billion earnings by 2028. This requires 5.4% yearly revenue growth and about a $0.7 billion earnings increase from $2.1 billion today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/materials/nyse-ecl/ecolab/yfhdr21m-margin-expansion-and-digital-solutions-will-drive-outperformance-over-the-next-few-years\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Ecolab's forecasts yield a $321.86 fair value</a>, a 4% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/materials/nyse-ecl/ecolab\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ECL 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/d6fac529-b8e4-48e7-b7f2-ccd2cab9639b/chart/quote-price\" width=\"746\"/></a><figcaption>ECL 1-Year Stock Price Chart</figcaption></figure> <p>Four members of the Simply Wall St Community estimate Ecolab‚Äôs fair value between US$233.30 and US$321.86, highlighting very different expectations. You should weigh these views against the risk that softer heavy industrial demand and rising input costs could pressure margins if Ecolab‚Äôs pricing and efficiency efforts underperform.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/materials/nyse-ecl/ecolab\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 4 other fair value estimates on Ecolab</a> - why the stock might be worth as much as $321.86!</p><h2>Form Your Own Verdict</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Ecolab research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/materials/nyse-ecl/ecolab\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/materials/nyse-ecl/ecolab\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Ecolab research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ecolab's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 smaller AI-focused companies with strong growth potential</a> through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Ecolab might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/materials/nyse-ecl/ecolab/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 08:35:59",
            "link": "https://simplywall.st/stocks/us/materials/nyse-ecl/ecolab/news/how-investors-are-reacting-to-ecolab-ecl-co-coo-reshuffle-an",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why Iovance Biotherapeutics (IOVA) Is Up 34.5% After Amtagvi-Fueled Revenue Jump And Lifileucel Fast Track",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Iovance Biotherapeutics recently reported Q4 2025 and full-year 2025 results, with revenue rising to US$86.77 million for the quarter and US$263.50 million for the year, alongside lower quarterly net loss and loss per share compared with 2024.</li> <li>At the same time, the company highlighted positive early lifileucel data in aggressive soft tissue sarcomas and secured FDA Fast Track designation for non-small cell lung cancer, underscoring how its first commercial TIL therapy Amtagvi is increasingly being leveraged across a broader pipeline.</li> <li>Next, we‚Äôll examine how the strong Amtagvi-driven revenue growth and Fast Track status for lifileucel influence Iovance‚Äôs investment narrative.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Iovance Biotherapeutics Investment Narrative Recap</h2><p>To own Iovance today, you need to believe Amtagvi can anchor a sustainable TIL franchise while lifileucel label expansions meaningfully broaden its reach. The latest results reinforce Amtagvi‚Äôs commercial traction but do not remove the key short term risk that the business is still loss making with a limited cash runway. The main near term catalyst remains further regulatory and clinical progress for lifileucel in new indications, especially non small cell lung cancer.</p> <p>The most relevant update is the FDA Fast Track designation for lifileucel in second line non small cell lung cancer, alongside positive sarcoma data and plans for a registrational soft tissue sarcoma trial. Together with Amtagvi driven revenue of US$86.77 million in Q4 2025 and a 61% full year revenue increase, this reinforces Iovance‚Äôs push to turn a single product melanoma story into a broader solid tumor platform.</p> <p>Yet in contrast to the recent momentum, investors should be aware that Iovance still has less than one year of cash runway and...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/5ucubww8-iova-advanced-melanoma-approval-and-equity-raise-will-drive-upside-potential\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Iovance Biotherapeutics (it's free!)</a></p><p>Iovance Biotherapeutics' narrative projects $744.8 million revenue and $35.6 million earnings by 2028. This requires 45.6% yearly revenue growth and a $425.5 million earnings increase from -$389.9 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/5ucubww8-iova-advanced-melanoma-approval-and-equity-raise-will-drive-upside-potential\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Iovance Biotherapeutics' forecasts yield a $8.35 fair value</a>, a 116% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"IOVA 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/quote-price\" width=\"746\"/></a><figcaption>IOVA 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest ranked analysts were assuming revenue of about US$524 million by 2028 and no profitability by then, which is far more pessimistic than the consensus view. When you compare that to today‚Äôs strong Amtagvi uptake and new Fast Track status, it shows how widely opinions can differ, and why it is worth weighing several viewpoints before you decide what this latest news could mean for your own expectations.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 10 other fair value estimates on Iovance Biotherapeutics</a> - why the stock might be worth 48% less than the current price!</p><h2>Form Your Own Verdict</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Iovance Biotherapeutics research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Iovance Biotherapeutics research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Iovance Biotherapeutics' overall financial health at a glance.</li></ul><h2>Seeking Other Investments?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 best rare earth metal stocks</a> of the very few that mine this essential strategic resource.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 08:26:43",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/why-iovance-biotherapeutics-iova-is-up-345-after-amtagvi-fue",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "ESAB Ruffian Launch And Linde Tie Up Put Valuation In Focus",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>ESAB (NYSE:ESAB) has introduced the Ruffian EMP 270G engine-driven welding generator at CONEXPO-CON/AGG 2026.</li> <li>The unit features advanced inverter technology and more than 100 customer-requested features.</li> <li>The product was developed in collaboration with Linde, with exclusive offerings tied to the trade show launch.</li> </ul> <p>ESAB, listed on the NYSE under the ticker ESAB, is a welding and cutting equipment company with a focus on industrial and construction applications. By rolling out the Ruffian EMP 270G at a major industry trade show, the company is putting a spotlight on its welding generator line and its use of inverter technology. The partnership with Linde adds another layer of interest for investors watching how ESAB works with large industrial gas and equipment players.</p> <p>For investors, this launch is mainly about how ESAB responds to customer feedback and expands its product set in engine-driven welding solutions. The combination of more than 100 customer-requested features and a high-profile debut at CONEXPO-CON/AGG 2026 provides additional information to consider when assessing ESAB's positioning in welding equipment and related services.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">ESAB</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/ESAB\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on ESAB.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:ESAB Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/105ba43f-a8da-48dd-b593-5b41ed742ebc/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:ESAB Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_full_picture\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab\" rel=\"noopener noreferrer\" target=\"_blank\">üì∞ Beyond the headline: 1 risk and 2 things going right for ESAB that every investor should see.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Investor Checklist</h2> <h3>Quick Assessment</h3> <ul> <li><strong>‚öñÔ∏è Price vs Analyst Target</strong>: ESAB trades at US$126.17 versus an analyst consensus of US$147.70, roughly 17% below the target.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Shares are described as trading about 10.7% below an estimated fair value.</li> <li><strong>‚úÖ Recent Momentum</strong>: The 30 day return of about 7.3% points to positive short term sentiment.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold ESAB. Head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of ESAB's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä The Ruffian EMP 270G launch highlights ESAB's focus on advanced inverter welding gear and customer requested features, which may influence how you view its product strength in Machinery.</li> <li>üìä Keep an eye on adoption of the new generator, any follow on product updates from the Linde partnership, and how these feed into revenue, earnings and ESAB's 30.5x P/E versus the Machinery industry average of about 28.4x.</li> <li>‚ö†Ô∏è ESAB carries a flagged risk of a high level of debt, so funding of new product lines and any future investment tied to this launch may be sensitive to balance sheet strength.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab\" rel=\"noopener noreferrer\" target=\"_blank\">complete ESAB analysis</a>. Alternatively, you can check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/ESAB\" rel=\"noopener noreferrer\" target=\"_blank\">community page for ESAB</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if ESAB might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/capital-goods/nyse-esab/esab/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 08:26:43",
            "link": "https://simplywall.st/stocks/us/capital-goods/nyse-esab/esab/news/esab-ruffian-launch-and-linde-tie-up-put-valuation-in-focus",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "BrightSpring Health Services (BTSG) EPS Jump In Q4 2025 Tests Bullish Profitability Narrative",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>BrightSpring Health Services (BTSG) just closed FY 2025 with fourth quarter revenue of US$3.6b and basic EPS of US$0.24, while net income from continuing operations, excluding extra items, came in at US$49.3m. The company has seen quarterly revenue move from US$3.1b and EPS of US$0.08 in Q4 2024 to US$3.6b and EPS of US$0.24 in Q4 2025, with trailing twelve month EPS at US$0.53 and net income of US$106.3m on US$12.9b in revenue. This puts the latest report firmly in focus for anyone tracking the shift in profitability. With that backdrop, the key question for investors is how durable these margins look as the business scales through its current run rate.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for BrightSpring Health Services.</a> <p>With the headline figures on the table, the next step is to set these results against the widely held stories about BrightSpring, highlighting where the numbers back up those narratives and where they start to pull in a different direction.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/3c9bqp32-aging-population-will-transform-home-and-community-integrated-care\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about BrightSpring Health Services</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:BTSG Revenue &amp; Expenses Breakdown as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4d909117-a897-44c6-8010-8d5f1f30d8de/chart/revenue-and-expenses-breakdown?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGS:BTSG Revenue &amp; Expenses Breakdown as at Feb 2026</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>TTM profit of US$106m after prior year loss</h2> <ul> <li>On a trailing twelve month basis, BrightSpring moved from a net loss of US$18.1m a year ago to net income of US$106.3m on US$12.9b of revenue.</li> <li>Consensus narrative highlights specialty pharmacy growth and efficiency projects as long term supports for earnings, and this swing into profitability lines up with that view, although:\n    <ul> <li>TTM basic EPS moved from a loss of US$0.09 to a profit of US$0.53, which fits the story of improving economics but still leaves EPS modest relative to the company‚Äôs US$41.43 share price.</li> <li>Over the past five years, earnings growth averaged a 7.4% annual decline. The recent profit contrasts with that history, so investors may treat it as early confirmation rather than a settled trend.</li> </ul> </li> </ul> <h2>Quarterly EPS climbs from US$0.05 to US$0.24</h2> <ul> <li>Within FY 2025, basic EPS moved from roughly US$0.05 in Q1 and Q2 to US$0.19 in Q3 and US$0.24 in Q4, alongside revenue rising from US$2.9b to US$3.6b over the same period.</li> <li>Bulls argue that operational improvements and specialty pharmacy momentum can keep lifting margins, and the step up in quarterly EPS speaks to that argument, but with some caveats:\n    <ul> <li>Net income, excluding extra items, increased from about US$9.7m in Q1 to US$49.3m in Q4, which strongly supports the bullish idea that the model can generate higher profit as volume scales.</li> <li>At the same time, bears point to high labor and compliance costs as ongoing pressures, and the relatively low TTM EPS of US$0.53 versus the US$41.43 share price shows that profitability is still at an early stage compared to the valuation implied by the P/E of 80.5x.</li> </ul> </li> </ul> Have the recent margin gains really changed the long term story, or are they just the first chapter in a bigger shift the bulls are hoping for, <a class=\"company-report-links\" data-vars-link-type=\"cta_bull_narrative_link\" href=\"https://simplywall.st/narratives/3c9bqp32-aging-population-will-transform-home-and-community-integrated-care\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêÇ BrightSpring Health Services Bull Case</strong></a> <h2>80.5x P/E and weak interest cover</h2> <ul> <li>The stock currently trades on a P/E of 80.5x, compared with 47x for peers and 23.7x for the wider US Healthcare sector, and interest payments are flagged as not well covered by earnings.</li> <li>Bears focus on this combination of premium multiple and balance sheet risk, and the latest numbers give them several points to work with:\n    <ul> <li>Even after reaching TTM net income of US$106.3m and EPS of US$0.53, the high P/E suggests investors are paying a large multiple of current earnings while interest coverage is described as weak, which can matter if earnings vary.</li> <li>Against that, the same dataset points to forecast earnings growth of about 29.5% a year and revenue growth around 13% a year, plus a DCF fair value of US$144.01, so the valuation debate sits between a rich current multiple and a much higher modelled DCF fair value.</li> </ul> </li> </ul> If you are weighing that rich P/E against the debt and interest coverage concerns, it can help to see how cautious analysts frame the downside, <a class=\"company-report-links\" data-vars-link-type=\"cta_bear_narrative_link\" href=\"https://simplywall.st/narratives/5lp8tja2-rising-healthcare-labor-and-regulation-will-hurt-margins-despite-automation\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêª BrightSpring Health Services Bear Case</strong></a> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/3c9bqp32-aging-population-will-transform-home-and-community-integrated-care\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for BrightSpring Health Services on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>Given the mix of confidence and concern running through this update, it makes sense to look at the details yourself and decide quickly where you stand. A helpful way to round out that view is to weigh the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> against the latest results and narratives.</p> <h2>See What Else Is Out There</h2> <p>BrightSpring‚Äôs 80.5x P/E, modest TTM EPS of US$0.53 against a US$41.43 share price, weak interest cover, and recent loss history all signal valuation and risk concerns.</p> <p>If that mix of rich pricing and balance sheet pressure feels uncomfortable, you might want to quickly check companies in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">76 resilient stocks with low risk scores</a> that aim to pair earnings quality with lower financial strain.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if BrightSpring Health Services might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 08:26:43",
            "link": "https://simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/news/brightspring-health-services-btsg-eps-jump-in-q4-2025-tests",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Charles Schwab Weighs Forge Deal And AI Pressure For Future Growth",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Charles Schwab (NYSE:SCHW) is moving to acquire Forge Global Holdings to expand its private market offerings.</li> <li>The deal is intended to give Schwab clients access to a broader range of private company investments.</li> <li>At the same time, new AI tools such as Altruist's AI powered tax product are increasing technology pressure across wealth management.</li> </ul> <p>For you as an investor, this combination of events ties directly to how Schwab positions itself in wealth management and trading. The firm already sits at the center of brokerage, advisory, and custody services, and private markets are an increasingly important area for clients who want more than public stocks and bonds. The move toward private offerings is happening as digital competitors lean hard into automation and AI driven experiences.</p> <p>Schwab's Forge deal and the broader push into private markets and technology could influence how it allocates capital, prioritizes product development, and responds to new entrants. As AI driven tools spread, the question for investors is how effectively incumbents like Schwab integrate similar capabilities into their platforms and keep their large existing customer bases engaged.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Charles Schwab</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/SCHW\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Charles Schwab.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:SCHW Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/25de5f1e-74d7-4741-a39c-54d8c1f163c5/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:SCHW Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_hidden_strengths\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab\" rel=\"noopener noreferrer\" target=\"_blank\">4 things going right for Charles Schwab that this headline doesn't cover.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At US$95.20 versus a US$121.00 consensus target, the price sits about 21% below where analysts on average think it could be.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: The shares are trading at roughly 11.6% below Simply Wall St's estimate of fair value.</li> <li><strong>‚ùå Recent Momentum</strong>: The 30 day return of about 8% decline shows recent weakness despite the deal headlines.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold Charles Schwab. Head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of Charles Schwab's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä The Forge Global acquisition ties Schwab more closely to private markets, which could matter for how its capital markets profile and fee mix develop over time.</li> <li>üìä Keep an eye on how Schwab discusses technology spend, AI features and integration of Forge on future earnings calls and in filings.</li> <li>‚ö†Ô∏è One flagged risk is recent insider selling, which some investors may weigh against the current valuation and the new growth initiatives.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab\" rel=\"noopener noreferrer\" target=\"_blank\">complete Charles Schwab analysis</a>. Alternatively, you can visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/SCHW\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Charles Schwab</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 08:26:42",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab/news/charles-schwab-weighs-forge-deal-and-ai-pressure-for-future",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Warner Bros. Discovery (WBD) One Off US$2.4b Gain Tests Bullish Profitability Narratives",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Warner Bros. Discovery (WBD) has capped FY 2025 with fourth quarter revenue of US$9.5b and a basic EPS loss of US$0.10, setting the tone for a year where profitability on a trailing basis has been supported by a sizeable one off gain. The company has seen quarterly revenue range between US$9.0b and US$9.8b across 2025, with EPS swinging from a loss of US$0.18 in Q1 to a profit of US$0.64 in Q2 before reverting to losses in Q3 and Q4. This leaves investors focusing on how much of the reported margin profile is driven by recurring operations versus that single US$2.4b boost. Overall, the latest numbers present a mixed margin picture that puts quality and durability of earnings at the centre of the earnings debate.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/us/media/nasdaq-wbd/warner-bros-discovery\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Warner Bros. Discovery.</a> <p>With the headline figures on the table, the next step is to set these results against the prevailing Warner Bros. Discovery narratives to see which stories about growth, profitability and risk still hold up and which ones the numbers start to challenge.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/mi9aav36-update-for-warner-bros-discovery\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about Warner Bros. Discovery</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/media/nasdaq-wbd/warner-bros-discovery/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:WBD Revenue &amp; Expenses Breakdown as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/5a050647-4c64-4012-a6f4-279b470786bf/chart/revenue-and-expenses-breakdown?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGS:WBD Revenue &amp; Expenses Breakdown as at Feb 2026</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Profitability helped by US$2.4b one off gain</h2> <ul> <li>On a trailing 12 month basis, Warner Bros. Discovery reports Basic EPS of US$0.29 and net income of US$727 million on US$37.3b of revenue, with management indicating that a single US$2.4b gain is a key part of that profit picture.</li> <li>Bulls argue that expanding use of franchises like Harry Potter, DC, Lord of the Rings and broader monetization of the content library can sustain earnings beyond this. However, the reliance on a large one off gain means investors have to separate recurring profitability from that US$2.4b boost.\n    <ul> <li>The bullish narrative points to multi channel revenue from theatrical, streaming, gaming, merchandise and experiences as support for earnings, while the latest year still shows three loss making quarters at the EPS level.</li> <li>Supporters of the bullish view highlight international expansion and partnerships, but the mixed quarterly net income profile, with Q1, Q3 and Q4 all reporting losses, gives a more cautious backdrop for those long term assumptions.</li> </ul> </li> </ul> <p>Bulls who think the content engine can outgrow that US$2.4b one off gain may want to see how that optimistic storyline stacks up against the full set of assumptions in the dedicated bull case for Warner Bros. Discovery. <a class=\"company-report-links\" data-vars-link-type=\"cta_bull_narrative_link\" href=\"https://simplywall.st/narratives/nz06t2qq-global-digital-trends-and-evergreen-ip-will-transform-entertainment-qsri\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêÇ Warner Bros. Discovery Bull Case</strong></a></p> <h2>High P/E and modest growth forecasts</h2> <ul> <li>The trailing P/E sits at 96.1x compared with 37x for the US Entertainment industry and 39.9x for peers, while forecasts call for earnings growth of about 9.3% per year and revenue growth of about 1.2% per year.</li> <li>Consensus narrative suggests that leveraging iconic IP and global sports plus cost discipline can support higher margins and cash flow. Yet the combination of a high P/E and modest growth expectations gives that story a relatively tight margin for error.\n    <ul> <li>Analysts expecting roughly 9.3% annual earnings growth are effectively asking the current 96.1x P/E to be supported by mid single digit style earnings growth and low single digit revenue growth.</li> <li>At the same time, revenue growth forecasts of about 1.2% per year running behind broader US market expectations sit awkwardly next to a P/E that is more than double the industry average.</li> </ul> </li> </ul> <h2>Debt costs sit against weak interest coverage</h2> <ul> <li>Analysts flag that interest payments are not well covered by earnings, which is a major financial risk even though the company has reported US$727 million of trailing 12 month net income and positive EPS on that basis.</li> <li>Bears argue that heavy debt, rising content costs and streaming competition could compress margins further, and the weak interest coverage data point gives that cautious view solid grounding.\n    <ul> <li>The fact that interest is not well covered comes alongside a mixed quarterly earnings record for FY 2025, with three out of four quarters showing net losses even before extra items.</li> <li>Critics highlight that if earnings growth comes in below the roughly 9.3% forecast, the company would have less flexibility to handle interest costs that are already described as not well covered.</li> </ul> </li> </ul> <p>Investors who focus on balance sheet resilience and the risk around interest coverage may want to see how the cautious camp lays out its arguments in the dedicated bear case for Warner Bros. Discovery. <a class=\"company-report-links\" data-vars-link-type=\"cta_bear_narrative_link\" href=\"https://simplywall.st/narratives/k1xv3y7f-margin-compression-and-debt-load-will-cripple-streaming-profitability-rwfk\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêª Warner Bros. Discovery Bear Case</strong></a></p> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/mi9aav36-update-for-warner-bros-discovery\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for Warner Bros. Discovery on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>After weighing both the bullish and cautious angles, the real question is how you see the balance between risk and reward. Move quickly, review the underlying data yourself and let our breakdown of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/media/nasdaq-wbd/warner-bros-discovery\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a> help you form a clear view.</p> <h2>See What Else Is Out There</h2> <p>WBD combines a very high 96.1x P/E, modest forecast growth and weak interest coverage, with profitability heavily influenced by a single US$2.4b gain.</p> <p>If concentration risk around debt and uneven earnings bothers you, consider checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">76 resilient stocks with low risk scores</a> to focus on companies with more resilient profiles.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Warner Bros. Discovery might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/media/nasdaq-wbd/warner-bros-discovery/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 08:26:42",
            "link": "https://simplywall.st/stocks/us/media/nasdaq-wbd/warner-bros-discovery/news/warner-bros-discovery-wbd-one-off-us24b-gain-tests-bullish-p",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Acuity Brands (AYI) Valuation After Strong Earnings And Cautious Guidance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Acuity (AYI) is back in focus after reporting a strong quarter, with revenue up 20.2% year on year and EBITDA and adjusted operating income ahead of estimates. However, the stock has fallen since earnings.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-ayi/acuity\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Acuity.</a></p> <p>The recent pullback, including a 17.7% 3 month share price decline and year to date share price return of negative 19.2%, contrasts with a 5 year total shareholder return of 142.2%. This suggests long term momentum while shorter term sentiment has cooled after earnings and guidance.</p> <p>If this mix of strong results and cautious sentiment has you looking around the sector, it could be a moment to check out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> as a source of other grid focused opportunities tied to electrification and building systems.</p> <p>With shares down over the past quarter yet trading at what looks like roughly a 20% intrinsic discount and close to 30% below analyst targets, is Acuity now mispriced, or is the market already accounting for all the future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 22.9% Undervalued</h2> <p>With Acuity last closing at $301.59 and the most followed narrative pointing to a fair value of $391.25, the gap between price and projected value is hard to ignore.</p> <blockquote> <p><em>The recent acquisition of QSC, which improves Acuity's capabilities in built space management and cloud connectivity, is expected to contribute to future sales growth and margin expansion in the Acuity Intelligence Spaces segment.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/9obif0ug-ayi-margin-expansion-and-operational-efficiencies-will-support-balanced-outlook\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious how one acquisition and a step up in electronics, pricing, and overseas reach feed into that fair value? The narrative leans on a firm earnings path and a richer margin profile than today, plus a future earnings multiple that sits below what is currently implied for the broader Electrical industry. The full story is in how those pieces add up, and what that could mean if the current discount ever closes.</p> <p><strong>Result: Fair Value of $391.25 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/9obif0ug-ayi-margin-expansion-and-operational-efficiencies-will-support-balanced-outlook\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, that upside view still hinges on tariffs not putting sustained pressure on margins and on the QSC integration delivering as planned rather than slipping.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-ayi/acuity\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Acuity narrative.</a></p> <h2>Next Steps</h2> <p>If the mix of long term momentum and recent caution leaves you unsure, act while the data is fresh and evaluate it for yourself. To see what is driving optimism, take a closer look at the <a class=\"company-report-links\" data-vars-link-type=\"cta_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-ayi/acuity\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If you stop here, you risk missing other stocks that could fit your plan just as well as Acuity, so consider widening your lens before you move on.</p> <ul> <li>Target potential value opportunities by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that currently screen well on quality and pricing metrics.</li> <li>Strengthen your core holdings by checking out the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (39 results)</a> that pair financial resilience with straightforward, transparent fundamentals.</li> <li>Get ahead of the crowd by reviewing a <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that may not be widely followed yet but still clear key quality filters.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 08:21:34",
            "link": "https://simplywall.st/stocks/us/capital-goods/nyse-ayi/acuity/news/a-look-at-acuity-brands-ayi-valuation-after-strong-earnings",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is It Time To Reassess Viavi Solutions (VIAV) After Its Recent Share Price Surge",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Viavi Solutions' share price still lines up with its fundamentals, this article will walk through what the current market price might be implying about value.</li> <li>At a last close of US$29.71, the stock has recent returns of 7.9% over 7 days, 41.3% over 30 days, 63.7% year to date, 165.7% over 1 year and 177.4% over 3 years, compared with 91.2% over 5 years.</li> <li>Recent news coverage has focused on Viavi Solutions' position within communications test and measurement and its role in supporting network build outs and technology rollouts. This helps frame how investors might think about the business backdrop to these returns. Commentary has also highlighted how investors are paying closer attention to companies exposed to connectivity and network infrastructure, which can influence how the market prices risk and potential.</li> <li>Despite these share price moves, Viavi Solutions holds a valuation score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-viav/viavi-solutions/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">1 out of 6</a>, so we will look at what different approaches like P/E, multiples and cash flow based estimates suggest about the current price. We then finish with a broader way of thinking about value that can round out those numbers.</li> </ul> <p>Viavi Solutions scores just 1/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-viav/viavi-solutions/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Viavi Solutions Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model looks at the cash Viavi Solutions is expected to generate in the future and discounts those projections back to today using a required rate of return. The idea is to estimate what all those future cash flows are worth in today's dollars.</p> <p>For Viavi Solutions, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $74.64 million. Analyst and extrapolated projections, provided in the model, run out to 2035 and show free cash flow estimates reaching $536.31 million in that year, all expressed in US$ and then discounted back to the present.</p> <p>Pulling those discounted cash flows together, the model arrives at an estimated intrinsic value of about US$29.42 per share. Against a recent market price of US$29.71, the DCF suggests the stock is around 1.0% overvalued, which is a very small gap and well within any reasonable margin of error.</p> <p><strong>Result: ABOUT RIGHT</strong></p> <p>Viavi Solutions is fairly valued according to our <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_fairly_valued\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-viav/viavi-solutions/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Discounted Cash Flow (DCF)</a>, but this can change at a moment's notice. Track the value in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_fairly_valued\" href=\"https://www.simplywall.st/watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_fairly_valued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted on when to act.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/tech/nasdaq-viav/viavi-solutions/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"VIAV Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/60159ccf-24da-4367-a61f-bab4fb6b4742/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>VIAV Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-viav/viavi-solutions/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Viavi Solutions.</a></p> <h3>Approach 2: Viavi Solutions Price vs Sales</h3> <p>For a company like Viavi Solutions, where investors often focus on revenue rather than net income, the P/S ratio is a useful way to think about what you are paying for each dollar of sales. Higher expected growth and lower perceived risk usually justify a higher P/S multiple. In contrast, slower expected growth or higher risk tend to pull that ‚Äúnormal‚Äù range down.</p> <p>Viavi Solutions currently trades on a P/S of 5.53x. That sits above both the Communications industry average P/S of 1.92x and the peer average of 2.91x, so the market is attaching a richer sales multiple than these broad benchmarks.</p> <p>Simply Wall St‚Äôs Fair Ratio for Viavi Solutions is 6.07x. This is a proprietary estimate of what the P/S might be given factors such as earnings growth, profit margins, industry, market cap and specific risks. Because it looks at these company level characteristics rather than just simple peer or industry comparisons, it can give a more tailored sense of what ‚Äúfair‚Äù could look like.</p> <p>Putting that beside the current 5.53x P/S, Viavi Solutions is priced below the 6.07x Fair Ratio on this metric.</p> <p><strong>Result: UNDERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/tech/nasdaq-viav/viavi-solutions/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:VIAV P/S Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/60159ccf-24da-4367-a61f-bab4fb6b4742/chart/ps-multiple-vs-industry?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGS:VIAV P/S Ratio as at Feb 2026</figcaption></figure> <p>P/S ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Viavi Solutions Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St's Community page you can use Narratives to write the story behind your numbers for Viavi Solutions. You can link your view of its future revenue, earnings and margins to a forecast and fair value, then compare that fair value with the current price to help decide when to buy or sell. The Narrative automatically updates when new news or earnings arrive. Different investors can, for example, plug in a more optimistic view closer to the US$26.07 fair value with higher assumed growth and margins, or a more cautious view closer to US$12.00 with tighter assumptions and a lower P/E, even though both are using the same company and data.</p> <p>Do you think there's more to the story for Viavi Solutions? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGS/VIAV\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/tech/nasdaq-viav/viavi-solutions\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:VIAV 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/60159ccf-24da-4367-a61f-bab4fb6b4742/chart/quote-price?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGS:VIAV 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 08:21:34",
            "link": "https://simplywall.st/stocks/us/tech/nasdaq-viav/viavi-solutions/news/is-it-time-to-reassess-viavi-solutions-viav-after-its-recent",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Bristol-Myers Squibb Cancer Advances Test Valuation Gap For Investors",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Bristol-Myers Squibb (NYSE:BMY) and SystImmune report highly positive Phase 3 interim results for izalontamab brengitecan in advanced triple-negative breast cancer.</li> <li>The trial shows significant gains in progression-free survival and overall survival for patients in a hard-to-treat cancer setting.</li> <li>The FDA accepts the new drug application for iberdomide for multiple myeloma, granting Breakthrough Therapy Designation and Priority Review.</li> <li>Iberdomide is described as a first-in-class cereblon E3 ligase modulator for patients with multiple myeloma.</li> </ul> <p>Bristol-Myers Squibb, traded as NYSE:BMY, is a large biopharmaceutical company focused on oncology, hematology, immunology, and cardiovascular disease. These new data on izalontamab brengitecan and the regulatory progress for iberdomide add to its presence in cancer and blood disorder treatments, areas that remain central for many global drug makers. For investors, this kind of late stage pipeline activity is often considered alongside marketed drugs when assessing a broad biopharma story.</p> <p>Readers will likely watch for full Phase 3 results on izalontamab brengitecan, the FDA‚Äôs decision on iberdomide, and any updates on potential label scope or target patient populations. These events may shape how the market views Bristol-Myers Squibb‚Äôs longer term product mix and research focus, while the fundamental risks associated with drug development and regulation remain important considerations.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Bristol-Myers Squibb</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/BMY\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Bristol-Myers Squibb.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:BMY Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4d208582-c6d4-4830-9a46-48803ea591cb/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:BMY Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 3 risks for Bristol-Myers Squibb. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Investor Checklist</h2> <h3>Quick Assessment</h3> <ul> <li><strong>‚öñÔ∏è Price vs Analyst Target</strong>: At US$62.37, the share price is roughly in line with the US$62.16 analyst price target.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: The shares are described as trading 48.4% below estimated fair value, which suggests a wide valuation gap.</li> <li><strong>‚úÖ Recent Momentum</strong>: The 30 day return of 14.9% indicates a strong short term move, potentially linked to positive trial and FDA news.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold Bristol-Myers Squibb. Head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of Bristol-Myers Squibb's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä Successful Phase 3 results in advanced breast cancer and FDA Priority Review for iberdomide add two late stage assets to the story in oncology and hematology.</li> <li>üìä Watch how these programs progress to potential approvals, as well as any updates on label scope, since they could influence future revenue mix and capital allocation.</li> <li>‚ö†Ô∏è One major flagged risk is that earnings are forecast to decline by an average of 0.04% per year over the next 3 years, which may temper enthusiasm around the clinical headlines.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb\" rel=\"noopener noreferrer\" target=\"_blank\">complete Bristol-Myers Squibb analysis</a>. Alternatively, you can visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/BMY\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Bristol-Myers Squibb</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Bristol-Myers Squibb might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 08:21:34",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-cancer-advances-test-valuation-gap-for",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Ziff Davis Refocuses On Core Business As RetailMeNot Bets On Cash Back",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>RetailMeNot, a Ziff Davis (NasdaqGS:ZD) company, has launched a Guaranteed Cash Back program that offers assured and stackable rewards for shoppers.</li> <li>Ziff Davis completed its exit from the Games Publishing business in Q4 2025, refocusing on its core operations.</li> </ul> <p>For you as an investor, these moves sit at the heart of what Ziff Davis does today: a mix of digital media, subscription based services, and advertising supported platforms. RetailMeNot‚Äôs Guaranteed Cash Back program reflects how retailers and brands are trying to keep customers engaged, and measurable performance marketing tools remain a key focus across the sector.</p> <p>The exit from Games Publishing removes a more content heavy, project driven activity from the NasdaqGS:ZD portfolio and aligns the company more tightly with its existing core operations. Together, these developments may influence how the business allocates capital across segments and how steady or variable its future revenue mix may look.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/media/nasdaq-zd/ziff-davis/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Ziff Davis</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NasdaqGS/ZD\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Ziff Davis.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/media/nasdaq-zd/ziff-davis/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:ZD Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/3cad906d-9c06-4cc1-912e-1e880e591d32/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGS:ZD Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/media/nasdaq-zd/ziff-davis\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 1 risk for Ziff Davis. See which could impact your investment.</a></p> <p>For Ziff Davis, RetailMeNot‚Äôs Guaranteed Cash Back rollout looks like an attempt to steady the Tech &amp; Shopping segment after an 18% Q4 revenue decline linked to weaker search traffic and affiliate commissions. A guaranteed 1% cash back across more than 4,000 merchants, some funded directly by RetailMeNot, gives retailers a clearer, performance based offer and could help shift the business mix from pure traffic driven affiliate revenues toward more direct, relationship based marketing spend. That may matter if search referrals remain pressured or if competitors such as Groupon and Honey keep pushing aggressive offers to retailers and brands.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Ziff Davis Narrative</h3> <ul> <li>The focus on RetailMeNot and exiting Games Publishing aligns with the narrative that Ziff Davis is concentrating on higher margin, recurring digital services and performance marketing, in line with its emphasis on SaaS like and subscription based revenue streams.</li> <li>The weak Q4, flat to slightly negative near term revenue commentary, and Tech &amp; Shopping headwinds challenge the idea that all core verticals can easily support ongoing revenue and margin expansion without further pressure.</li> <li>The Guaranteed Cash Back program and the decision to fully exit Games Publishing, while retaining rights to potential future performance payments, add more detail on how management is reacting to traffic shifts and AI driven content changes, which is not fully captured in the earlier high level growth narrative.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/sxkxg2vh-cloud-based-solutions-and-digital-advertising-will-drive-future-markets-bs1w\" rel=\"noopener noreferrer\" target=\"_blank\">Check out one of the top narratives in the Simply Wall St Community for Ziff Davis</a> to help decide what it is worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Q4 2025 net income fell sharply to US$0.37 million from US$64.09 million a year earlier, which shows how quickly profitability can compress when key segments weaken and one off items hit results.</li> <li>‚ö†Ô∏è The 18% revenue decline in Tech &amp; Shopping and management‚Äôs decision to defer 2026 guidance highlight uncertainty around search traffic trends, AI content licensing outcomes, and how quickly the company can adjust its model.</li> <li>üéÅ Full year 2025 revenue of US$1.45b versus US$1.40b a year earlier, strong free cash flow, and US$174 million in buybacks, including 30.48% of shares repurchased since 2020, show that Ziff Davis is using cash generation to reshape its capital structure.</li> <li>üéÅ Growth in Health &amp; Wellness, Connectivity, and Cybersecurity &amp; Martech, helped by AI powered data tools and increased pharma ad spend, suggests the company has businesses that are less dependent on search engine referrals than Tech &amp; Shopping.</li> </ul> <h3>What To Watch Going Forward</h3> <p>As a shareholder or potential investor, you may want to watch how quickly RetailMeNot‚Äôs Guaranteed Cash Back program translates into steadier Tech &amp; Shopping revenue, especially if search referral volumes stay under pressure. The company‚Äôs ongoing talks around AI content licensing with large platforms could influence both traffic and monetization, so any updates there will matter. It is also worth tracking whether management continues to exit or shrink lower return activities, similar to Games Publishing, and how that affects margins and earnings over the next few quarters. Finally, with share repurchases already reducing the share count by more than 10% in 2025, future capital allocation decisions, including any extension of the buyback program, will likely remain a key part of the story.</p> <p>To ensure you are always in the loop on how the latest news impacts the investment narrative for Ziff Davis, head to the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NasdaqGS/ZD\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Ziff Davis</a> to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Ziff Davis might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/media/nasdaq-zd/ziff-davis/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 08:21:34",
            "link": "https://simplywall.st/stocks/us/media/nasdaq-zd/ziff-davis/news/ziff-davis-refocuses-on-core-business-as-retailmenot-bets-on",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Installed Building Products (IBP) Valuation After Strong Recent Shareholder Returns",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Installed Building Products (IBP) has attracted fresh attention after recent share price moves, with the stock last closing at $327.76. Investors are weighing this level against the company‚Äôs recent returns and current valuation signals.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-durables/nyse-ibp/installed-building-products\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Installed Building Products.</a></p> <p>The latest move to $327.76 comes after a 22.55% year to date share price return and a 94.55% total shareholder return over the past year, which some investors may be reassessing against current valuation signals.</p> <p>If this kind of run has you thinking about what else is moving, it might be a good moment to scan a screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a> and see what stands out next.</p> <p>With the share price now at $327.76, recent returns, a value score of 0, and a discount of 13.82% to the average analyst price target, is there still a buying opportunity here, or is the market already pricing in future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 33.5% Overvalued</h2> <p>Compared with the latest fair value estimate of about $245.54, IBP‚Äôs $327.76 share price sits well above what the most followed narrative suggests, putting the focus on how future earnings and cash flows are expected to play out under that view.</p> <blockquote> <p><em>Current strong cash flow from operations is mainly attributed to working capital improvements rather than fundamental growth in net income, which may not be sustainable; any normalization in working capital could expose weaker core earnings and impact future cash flows.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/5f55awwv-declining-housing-starts-and-robust-backlog-will-shape-industry-trends-hc14\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what sort of revenue path, margin profile, and future earnings multiple sit behind that fair value cut to roughly the mid $240s? The narrative leans on modest growth, a premium P/E and a specific discount rate to bridge today‚Äôs price with tomorrow‚Äôs cash flows. However, the exact mix of those inputs is where the real story lives.</p> <p><strong>Result: Fair Value of $245.54 (OVERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/5f55awwv-declining-housing-starts-and-robust-backlog-will-shape-industry-trends-hc14\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, if multifamily and commercial demand stays firm and IBP continues to improve margins through operations and complementary products, that overvaluation narrative could come under pressure.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-durables/nyse-ibp/installed-building-products\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Installed Building Products narrative.</a></p> <h2>Next Steps</h2> <p>Seeing mixed signals on price and fair value so far? Take a closer look at the underlying data, weigh the upside and downside, and move quickly enough to form your own view using <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-durables/nyse-ibp/installed-building-products\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 1 important warning sign</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If IBP has you thinking more broadly about your portfolio, now is a good time to widen your watchlist using focused stock ideas from the Simply Wall St screener.</p> <ul> <li>Spot fresh value by scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that combine quality fundamentals with prices that differ from their underlying metrics.</li> <li>Strengthen your income stream by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that aim to pair higher yields with consistent payout records.</li> <li>Reduce potential portfolio shocks by checking <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">76 resilient stocks with low risk scores</a> that our model flags for more resilient risk profiles.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 08:21:34",
            "link": "https://simplywall.st/stocks/us/consumer-durables/nyse-ibp/installed-building-products/news/a-look-at-installed-building-products-ibp-valuation-after-st",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "BlueNord License Extension Invitation Reshapes Danish North Sea Value Story",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>BlueNord ASA (OB:BNOR) and its partners have been invited by the Danish government to explore an extension of their Danish Underground Consortium license.</li> <li>The potential extension would shift the current license expiry from 2042 to 2050.</li> <li>The proposal relates to BlueNord's core producing assets in the Danish North Sea.</li> </ul> <p>For you as an investor, this matters because the Danish Underground Consortium sits at the heart of BlueNord's oil and gas business. An extended license would keep its fields in play for longer, and this is occurring at a time when European governments are focused on energy security and stable domestic supply. The news directly connects BlueNord's operational footprint with long dated policy support from Denmark.</p> <p>If the license extension proceeds, it could lengthen BlueNord's production horizon and support the long term planning of capital spending and field development. Investors will likely watch how the dialogue with the authorities progresses, the conditions attached to any agreement, and how BlueNord (OB:BNOR) frames this within its broader energy transition and portfolio plans.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/no/energy/ob-bnor/bluenord-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">BlueNord</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/OB/BNOR\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on BlueNord.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/no/energy/ob-bnor/bluenord-shares/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"OB:BNOR Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/892e0a95-4069-4e21-93a5-9e6e7ed6d98c/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>OB:BNOR Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_hidden_strengths\" href=\"https://www.simplywall.st/stocks/no/energy/ob-bnor/bluenord-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 things going right for BlueNord that this headline doesn't cover.</a></p> <p>The invitation to extend the Danish Underground Consortium license sits neatly alongside several recent moves that shape how you might think about BlueNord as a long term partner to the Danish state. The company has just reported its highest quarterly production on record, outlined full year guidance around 25,000 barrels per day, and highlighted the Tyra hub‚Äôs maximum potential at about 30,000 barrels per day once stable operations are in place. At the same time, BlueNord has extended its US$1.4b reserve based lending facility to 2031 and added an Accordion option of up to US$400m. This gives the company additional financial flexibility for future commercial opportunities tied to these assets. For you, the key link is that a longer license life, more visible production from Tyra, and longer dated debt maturity all point to BlueNord framing the DUC as a core, cash generative hub that can support dividends, such as the proposed NOK 42.84 per share for Q4 2025, and ongoing investment. This is particularly relevant when you compare BlueNord with other North Sea focused players such as Aker BP, Harbour Energy or Var Energi, where field lives, license terms and financing arrangements also shape the long term profile.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The BlueNord Narrative</h3> <ul> <li>The potential license extension supports the narrative‚Äôs focus on Tyra and the DUC as long term production anchors that can underpin revenue and support BlueNord‚Äôs aim of returning a high share of operating cash flow to shareholders.</li> <li>Analysts in the narrative highlight high debt and financial obligations as a constraint, and while the extended lending facility provides flexibility, a longer license life could encourage further investment that keeps leverage and interest costs in focus.</li> <li>The narrative puts most of the emphasis on Tyra‚Äôs redevelopment and gas price assumptions, whereas the invitation to extend the DUC license to 2050 introduces a regulatory and policy dimension that may not be fully captured in those earlier expectations.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/f5b80muw-tyra-redevelopment-and-north-sea-gas-will-secure-long-term-stability-1v14\" rel=\"noopener noreferrer\" target=\"_blank\"> Check out one of the top narratives in the Simply Wall St Community for BlueNord</a> to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Analysts have flagged that earnings are expected to decline by an average of 2.5% per year over the next 3 years, which could limit how much value BlueNord can extract from a longer DUC license period.</li> <li>‚ö†Ô∏è Interest payments are described as not well covered by earnings, so more capital spending on extended field life or new projects could stretch the balance sheet if cash flows do not track expectations.</li> <li>üéÅ The company is assessed as trading at a very large discount to an estimate of its fair value, which means investors are currently paying a low price relative to that model if the long term DUC opportunity is realised.</li> <li>üéÅ BlueNord has recently become profitable and is proposing a sizeable dividend for Q4 2025, so a longer production horizon from the DUC may support its stated intention to return a high share of operating cash flow to shareholders.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, you will want to watch how negotiations with the Danish authorities progress, particularly any conditions around emissions, investment commitments or decommissioning that come with a license extension to 2050. Track whether Tyra can move from ramp up to stable production near the 30,000 barrels per day potential described by management, and how that compares to the 25,000 barrels per day guidance that already includes planned shutdowns. It is also worth monitoring how BlueNord uses its extended US$1.4b lending facility and US$400m Accordion option, and whether dividend plans such as the NOK 42.84 per share proposal remain aligned with production, cash flow and debt metrics. For context, comparing BlueNord‚Äôs capital returns, leverage and license life with peers like Aker BP, Harbour Energy and Var Energi can help you assess how differentiated this DUC opportunity really is.</p> <p>To ensure you're always in the loop on how the latest news impacts the investment narrative for BlueNord, head to the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/OB/BNOR\" rel=\"noopener noreferrer\" target=\"_blank\"> community page for BlueNord</a> to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if BlueNord might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/no/energy/ob-bnor/bluenord-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 08:15:55",
            "link": "https://simplywall.st/stocks/no/energy/ob-bnor/bluenord-shares/news/bluenord-license-extension-invitation-reshapes-danish-north",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is It Time To Reassess XPEL (XPEL) After Recent Share Price Pullback?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether XPEL at around US$42.62 is still reasonably priced or already stretching its value, this article is for you.</li> <li>The stock has had a mixed run, with a 27.5% gain over the past year but declines of 16.8% over 7 days, 18.4% over 30 days, and 15.2% year to date, which may change how you think about risk and reward here.</li> <li>Recent coverage has focused on XPEL's position in automotive protection products and how investors are reacting to that story. This helps frame these sharp short term moves. This mix of optimism and caution in the news is exactly why taking a closer look at the valuation now can be useful.</li> <li>XPEL currently scores 4 out of 6 on our valuation checks, giving it a value score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/automobiles/nasdaq-xpel/xpel/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">4/6</a>. Next, we will run through the standard valuation approaches before finishing with a more complete way to think about what the stock is worth.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_performance_contextual\" href=\"https://www.simplywall.st/stocks/us/automobiles/nasdaq-xpel/xpel/past\" rel=\"noopener noreferrer\" target=\"_blank\">XPEL delivered 27.5% returns over the last year. See how this stacks up to the rest of the Auto Components industry.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: XPEL Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model takes estimates of the cash a company may generate in the future and discounts those cash flows back to what they could be worth today. It is a way of asking what you might reasonably pay now for those projected future dollars.</p> <p>For XPEL, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The company‚Äôs last twelve months Free Cash Flow is about $58.9 million. Analyst inputs and Simply Wall St extrapolations suggest Free Cash Flow of $57.9 million in 2026, rising in steps to a projected $242.4 million in 2035, all in $. These amounts are discounted back to today using a required return, which results in an estimated intrinsic value per share of about $126.69.</p> <p>Compared with the recent share price around $42.62, the DCF output implies XPEL is trading at a 66.4% discount to this intrinsic value, which indicates a materially undervalued stock on this model.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests XPEL is undervalued by 66.4%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/automobiles/nasdaq-xpel/xpel/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"XPEL Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/358cfe36-d2c1-426c-b8a4-35a170d548cd/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>XPEL Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/automobiles/nasdaq-xpel/xpel/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for XPEL.</a></p> <h3>Approach 2: XPEL Price vs Earnings</h3> <p>For a profitable business like XPEL, the P/E ratio is a useful way to relate what you pay for each share to the earnings that support it. A higher or lower P/E usually reflects what the market expects for future earnings growth and how much risk investors feel they are taking on.</p> <p>XPEL currently trades on a P/E of about 23x. That sits below the peer group average of roughly 24.9x and slightly above the Auto Components industry average of about 20.7x. To go a step further, Simply Wall St calculates a ‚ÄúFair Ratio‚Äù of 20.6x for XPEL, which is the P/E level it might trade on given factors such as its earnings growth profile, profit margins, size, industry and key risks.</p> <p>This Fair Ratio approach can be more informative than comparing only with peers or the broad industry, because it adjusts for the specific characteristics of the company rather than assuming all businesses in the same group deserve the same multiple. With XPEL at 23x versus a Fair Ratio of 20.6x, the shares screen as somewhat expensive on this metric.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/automobiles/nasdaq-xpel/xpel/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:XPEL P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/358cfe36-d2c1-426c-b8a4-35a170d548cd/chart/pe-multiple-vs-industry?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqCM:XPEL P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your XPEL Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. Let us introduce Narratives, which are simple stories you create about XPEL that tie your view of its business, revenue, earnings and margins to a financial forecast and a fair value. You can compare that fair value to today‚Äôs price to help you decide whether you see the stock as attractive or not. You can then keep that view alive on Simply Wall St‚Äôs Community page, where millions of investors share Narratives that update automatically when new news or earnings arrive. In XPEL‚Äôs case you might, for example, align with a more optimistic community Narrative that sees fair value closer to US$55, or instead with a more cautious Narrative closer to US$38. By choosing which story feels more realistic to you, you turn scattered data into a clear, numbers backed view you can act on.</p> <p>Do you think there's more to the story for XPEL? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqCM/XPEL\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/automobiles/nasdaq-xpel/xpel\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:XPEL 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/358cfe36-d2c1-426c-b8a4-35a170d548cd/chart/quote-price?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqCM:XPEL 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 08:15:55",
            "link": "https://simplywall.st/stocks/us/automobiles/nasdaq-xpel/xpel/news/is-it-time-to-reassess-xpel-xpel-after-recent-share-price-pu",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is It Time To Reassess Immunocore (IMCR) After Recent Biotech Progress And Valuation Signals",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Immunocore Holdings is priced attractively right now, this article will walk through how its current share price stacks up against several valuation checks.</li> <li>The stock last closed at US$32.30, with a 10.0% return over the past year but declines of 1.2% over 7 days, 2.5% over 30 days and 4.4% year to date. These movements can change how investors think about both upside potential and risk.</li> <li>Recent news around Immunocore has focused on its position within the pharmaceuticals and biotech space and how the market is reacting to its progress on key treatments and partnerships. This backdrop helps explain why the share price has moved over different time frames, even without a single headline driving all of the shifts.</li> <li>On our valuation checks, Immunocore scores 5 out of 6, giving it a <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation score of 5</a>. Next we will walk through the methods behind that score and finish with a way to look beyond the numbers for an even fuller view of value.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_underperformer\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/future\" rel=\"noopener noreferrer\" target=\"_blank\">Find out why Immunocore Holdings's 10.0% return over the last year is lagging behind its peers.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Immunocore Holdings Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow model estimates what a company might be worth today by projecting its future cash flows and then discounting those projections back to a present value.</p> <p>For Immunocore Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $16.9 million. Analysts provide explicit free cash flow estimates out to 2030, with Simply Wall St extrapolating further. Within that, projected free cash flow in 2030 is $479.7 million, with interim figures for 2026 to 2035 ranging from $1.5 million to $704.3 million, all in dollar terms.</p> <p>Discounting these projected cash flows produces an estimated intrinsic value of about $189.83 per share. Compared with the recent share price of $32.30, the DCF output suggests the stock is 83.0% undervalued on this model.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Immunocore Holdings is undervalued by 83.0%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"IMCR Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/edea9913-d917-4ad7-b10e-3a17b28ddda2/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>IMCR Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Immunocore Holdings.</a></p> <h3>Approach 2: Immunocore Holdings Price vs Sales</h3> <p>For companies where earnings are not yet a steady guide, the P/S ratio can be a useful way to think about value because it focuses on how much investors are paying for each dollar of revenue.</p> <p>What counts as a reasonable P/S depends on how quickly revenue is expected to grow and how risky that growth path looks. Higher expected growth or lower perceived risk can often support a higher multiple, while slower growth or higher risk usually points to a lower, more cautious range.</p> <p>Immunocore currently trades on a P/S of 4.09x. That sits below the Biotechs industry average P/S of 12.43x and also below the peer average of 15.83x that Simply Wall St uses for similar companies. Simply Wall St also calculates a Fair Ratio of 7.80x, which is its view of an appropriate P/S once factors like earnings growth, industry, profit margin, market cap and company specific risks are taken into account.</p> <p>This Fair Ratio is often more useful than a simple peer or industry comparison because it adjusts for Immunocore‚Äôs own profile rather than assuming all companies deserve the same multiple. With the current P/S of 4.09x sitting below the Fair Ratio of 7.80x, the preferred multiple suggests the shares are trading at a discount to that model.</p> <p><strong>Result: UNDERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:IMCR P/S Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/edea9913-d917-4ad7-b10e-3a17b28ddda2/chart/ps-multiple-vs-industry?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGS:IMCR P/S Ratio as at Feb 2026</figcaption></figure> <p>P/S ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Immunocore Holdings Narrative</h3> <p>Earlier we mentioned that there is an even better way to think about valuation. On Simply Wall St that comes through Narratives, where you set out your own story about Immunocore Holdings, connect it to explicit assumptions for future revenue, earnings and margins, and let the platform translate that into a financial forecast, a fair value, and a simple Fair Value vs Price view that updates as new news or earnings arrive. All of this is within the Community page used by millions of investors, so you can quickly see, for example, how one investor‚Äôs optimistic view of a fair value around US$100 based on faster growth and a higher P/E contrasts with another investor‚Äôs cautious fair value near US$24.92 that leans on slower growth and a lower multiple. You can then decide which story, if either, lines up with how you see the company today.</p> <p>Do you think there's more to the story for Immunocore Holdings? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGS/IMCR\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:IMCR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/edea9913-d917-4ad7-b10e-3a17b28ddda2/chart/quote-price?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGS:IMCR 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 08:15:55",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-it-time-to-reassess-immunocore-imcr-after-recent-biotech",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Park Hotels Ties Finance And Operations With Sean Dell‚ÄôOrto Promotion",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Park Hotels &amp; Resorts (NYSE:PK) has appointed Sean M. Dell‚ÄôOrto as Chief Operating Officer, adding to his existing roles as Chief Financial Officer and Treasurer.</li> <li>The expanded role gives Dell‚ÄôOrto broader oversight of operations alongside his current finance responsibilities.</li> </ul> <p>For Park Hotels &amp; Resorts, which last closed at $11.31, this leadership shift puts one executive at the center of both financial and operational decisions. The stock shows mixed performance, with a 5.4% return over the past 30 days and 11.5% over 3 years, alongside a 23.5% decline over 5 years. That backdrop helps explain why investors may pay closer attention when the company adjusts its senior ranks.</p> <p>With Dell‚ÄôOrto stepping into the COO role while retaining CFO and Treasurer duties, the company is concentrating more responsibility in a single, experienced insider. Investors often watch how such changes translate into capital allocation choices, portfolio actions and day to day hotel operations. The coming quarters may reveal how this new structure shapes priorities for NYSE:PK.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/real-estate/nyse-pk/park-hotels-resorts/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Park Hotels &amp; Resorts</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/PK\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Park Hotels &amp; Resorts.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/real-estate/nyse-pk/park-hotels-resorts\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:PK 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/8ad76aeb-100c-4ef4-a61e-a0b78019f0b8/chart/quote-price?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:PK 1-Year Stock Price Chart</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_management\" href=\"https://www.simplywall.st/stocks/us/real-estate/nyse-pk/park-hotels-resorts/management\" rel=\"noopener noreferrer\" target=\"_blank\">Does the team leading Park Hotels &amp; Resorts have what it takes? See our full breakdown of the management team's track record and compensation.</a></p> <p>The timing of Sean Dell‚ÄôOrto‚Äôs expanded role comes right after a tough reporting year, with Park Hotels &amp; Resorts moving from net income of US$66 million in the fourth quarter of 2024 to a net loss of US$205 million in the fourth quarter of 2025, and from full year net income of US$212 million to a full year net loss of US$283 million. Having the same person oversee both the finance function and day to day operations could tighten the link between budgeting, capital allocation, refinancing plans and how individual hotels are run. That may matter given recent renovation disruption, asset sales and the focus on capital recycling highlighted by management. Investors can also set this appointment alongside the decision to keep returning cash through a US$0.25 per share first quarter 2026 dividend and the completion of a US$24.96 million buyback program covering about 1.03% of shares. With cautious 2026 earnings guidance and upcoming debt maturities referenced in recent commentary, Dell‚ÄôOrto‚Äôs combined responsibilities put more emphasis on execution discipline, especially around refinancing, any future asset sales and the performance of key resorts such as Hilton Hawaiian Village.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Park Hotels &amp; Resorts Narrative</h3> <ul> <li>Concentrating financial and operational oversight in one long tenured executive can support the narrative‚Äôs focus on reinvestment and portfolio reshaping by aligning capital decisions with on the ground execution at properties like Hilton Hawaiian Village and Royal Palm.</li> <li>The broader remit also highlights the pressure points raised in the narrative, such as leverage, refinancing needs and higher labor costs, which could make operational missteps more costly if execution falls short.</li> <li>The appointment formalizes Dell‚ÄôOrto‚Äôs role in coordinating internal operations with strategy, which is not fully reflected in the narrative‚Äôs emphasis on assets, demand trends and debt structure rather than leadership structure.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/27l7oe4i-renovations-and-asset-sales-will-unlock-premium-hotel-experiences-d69o\" rel=\"noopener noreferrer\" target=\"_blank\"> Check out one of the top narratives in the Simply Wall St Community for Park Hotels &amp; Resorts</a> to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Analysts have flagged that interest payments are not well covered by earnings, which makes the company‚Äôs refinancing plans and Dell‚ÄôOrto‚Äôs capital markets background especially important.</li> <li>‚ö†Ô∏è An unstable dividend track record and a recent move to a full year net loss of US$283 million add pressure on management to balance shareholder returns with balance sheet strength.</li> <li>üéÅ Earnings are forecast to grow at a high rate, and Dell‚ÄôOrto‚Äôs combined finance and operations oversight could help align hotel level performance with those expectations.</li> <li>üéÅ The company is viewed as trading at a discount to some estimates of fair value and at attractive levels compared with peers, which may appeal to investors who are comfortable with the operational and financial risks.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, you may want to watch how quickly Dell‚ÄôOrto‚Äôs expanded remit shows up in reported numbers, especially around margins at key resorts, progress on hotel renovations and any further asset sales. The next few earnings reports will give more clarity on whether the shift from net income in 2024 to a net loss in 2025 stabilizes, and how closely results track the 2026 net income guidance range of US$69 million to US$99 million. Debt refinancing activity, dividend decisions beyond the US$0.25 per share first quarter payout and any changes in capital returns policy will also be useful signals of how the new leadership structure is being used. To ensure you're always in the loop on how the latest news impacts the investment narrative for Park Hotels &amp; Resorts, head to the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/PK\" rel=\"noopener noreferrer\" target=\"_blank\"> community page for Park Hotels &amp; Resorts</a> to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 08:15:55",
            "link": "https://simplywall.st/stocks/us/real-estate/nyse-pk/park-hotels-resorts/news/park-hotels-ties-finance-and-operations-with-sean-dellorto-p",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is UWM Holdings (UWMC) Pricing In Too Much After Recent Share Price Weakness",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether UWM Holdings at US$4.41 is a bargain or a value trap, you are not alone. This article walks through what the current share price might be implying.</li> <li>The stock has seen a 4.5% decline over the last 7 days, a 25.1% decline over the past month, is flat year to date at 0.0%, has a 24.1% decline over 1 year, a 12.6% return over 3 years, and a 27.0% decline over 5 years, which can change how investors think about both risk and potential upside.</li> <li>Recent moves in UWM Holdings often sit against a backdrop of sector wide headlines around mortgage activity, interest rate expectations, and investor appetite for financials. These factors can influence sentiment even when company specific news is limited. For long term holders and new investors, this mix of broader industry chatter and shifting sentiment can matter as much as stock specific events when judging price action.</li> <li>On Simply Wall St's valuation checks, UWM Holdings currently scores <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-uwmc/uwm-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">0 out of 6</a>. Next we will look at what different valuation methods say about that number, and then finish by pointing you to an even more complete way of thinking about the stock's value.</li> </ul> <p>UWM Holdings scores just 0/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-uwmc/uwm-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: UWM Holdings Excess Returns Analysis</h3> <p>The Excess Returns model looks at how much return a company is expected to earn above its cost of equity, then converts that into a per share value. It asks a simple question: after paying shareholders for the risk they take, how much value is left over each year?</p> <p>For UWM Holdings, the model uses a Book Value of $0.74 per share and a Stable EPS of $0.14 per share, based on the median return on equity from the past 5 years. The Average Return on Equity is 10.48%, while the Cost of Equity is 9.51%. That gap feeds into an estimated Excess Return of $0.04 per share.</p> <p>Analysts also expect a Stable Book Value of $1.30 per share, based on weighted future book value estimates from 4 analysts. Combining these inputs, the Excess Returns model arrives at an intrinsic value of about $2.33 per share. Compared with the current share price of US$4.41, this framework suggests UWM Holdings is 89.3% overvalued on this measure.</p> <p><strong>Result: OVERVALUED</strong></p> <p>Our Excess Returns analysis suggests UWM Holdings may be overvalued by 89.3%. <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">Discover 46 high quality undervalued stocks</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">create your own screener</a> to find better value opportunities.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/diversified-financials/nyse-uwmc/uwm-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"UWMC Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/40322065-2f8a-4897-a1a8-1c1238d39194/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>UWMC Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-uwmc/uwm-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for UWM Holdings.</a></p> <h3>Approach 2: UWM Holdings Price vs Earnings</h3> <p>For profitable companies, the P/E ratio is a straightforward way to link what you pay for a share to the earnings that each share generates. It helps you see how many years of current earnings the market is effectively pricing in.</p> <p>What counts as a ‚Äúnormal‚Äù or ‚Äúfair‚Äù P/E depends on how the market views a company‚Äôs growth prospects and risk. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually lines up with a lower P/E.</p> <p>UWM Holdings is currently trading on a P/E of 47.49x. That sits above the Diversified Financial industry average of 17.81x and above the peer average of 8.20x. Simply Wall St‚Äôs Fair Ratio for UWM Holdings is 26.09x, which is its in house estimate of a P/E that fits the company‚Äôs earnings growth profile, industry, profit margins, market cap and risk factors.</p> <p>This Fair Ratio can be more useful than a simple peer or industry comparison because it adjusts for company specific traits rather than assuming all firms should trade on the same multiple. Set against the current 47.49x P/E, the 26.09x Fair Ratio points to UWM Holdings trading above what this framework suggests is justified.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/diversified-financials/nyse-uwmc/uwm-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:UWMC P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/40322065-2f8a-4897-a1a8-1c1238d39194/chart/pe-multiple-vs-industry?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:UWMC P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your UWM Holdings Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St you can use Narratives, where you tell the story behind your numbers by linking your view on UWM Holdings future revenue, earnings and margins to a forecast and fair value. You can then compare that to today‚Äôs price to see if your story points to opportunity or caution.</p> <p>A Narrative is simply your written explanation of what you think is driving the business, paired with your assumptions and a resulting fair value. It keeps everything in one place rather than scattered across notes and spreadsheets.</p> <p>On the UWM Holdings Community page, you can see Narratives that already exist on the platform, including more cautious views that line up with fair values around US$5.00 and more optimistic views closer to about US$9.20. You can decide which story feels closer to your own expectations.</p> <p>As new earnings, news or sector data come in, Narratives on Simply Wall St update with fresh inputs. The fair value attached to each story moves with the information and gives you a living reference point for whether your chosen Narrative still fits the current US$4.41 share price.</p> <p>Do you think there's more to the story for UWM Holdings? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NYSE/UWMC\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/diversified-financials/nyse-uwmc/uwm-holdings\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:UWMC 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/40322065-2f8a-4897-a1a8-1c1238d39194/chart/quote-price?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:UWMC 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 08:15:55",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nyse-uwmc/uwm-holdings/news/is-uwm-holdings-uwmc-pricing-in-too-much-after-recent-share",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}